WillItSurvive
Pharma and healthcare groups · United States

Boston Scientific

bostonscientific.com ↗

Medtech giant making cardiac, electrophysiology, and surgical devices.

Defensible for now
Assessed 20 July 2026 · Evidence as of 20 July 2026
Real protection, with named pressure against it.
On the recordSince 20 July 2026 · Checkable from July 29, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report, first full quarter after the February guidance cut
The call

Boston Scientific keeps growing overall sales, but its fastest-growing electrophysiology unit now faces three equally resourced rivals shipping competing devices.

Boston Scientific makes implants and catheters for heart problems, cancer, and other conditions, selling through hospitals and doctors worldwide. It is hard to replace because the FDA requires years of clinical trial data and hospitals trust established suppliers, but its newest heart rhythm business (FARAPULSE) faces direct competition from Medtronic, Johnson & Johnson, and Abbott who already sell similar devices. The company's stock has crashed and lawsuits have followed. The biggest wildcard is whether independent software companies could eventually handle the mapping and planning that Boston Scientific now does in-house by around 2027, though the physical devices themselves would still need to come from someone like this company.

Why
01
AI pressure: AI-driven procedural mapping software vendors targeting electrophysiology. AI mapping tools could erode the EP software layer by 2027, but the hardware itself stays largely AI-resistant. Could AI do the core job? Unlikely.
02
Bigger players: Medtronic, Biosense Webster (J&J), and Abbott Laboratories. All three rivals now ship competing PFA heart-ablation devices, pulling share from Boston Scientific's Farapulse system. Could a giant copy it? No, they are blocked.
03
What protects it. FDA approval hurdles, deep physician relationships, hospital contracts, and years of clinical trial data slow rivals from switching hospitals over.
What would change this call
Q2 2026 earnings on July 29, 2026 showing whether EP segment revenue/margin stabilizes or guidance is cut again. Would show whether Medtronic/J&J/Abbott are still taking PFA share or losses have leveled off.
FTC Second Request review outcome on the $14.5B Penumbra acquisition through 2026. Would show whether regulators block or clear a deal meant to offset EP pressure.
Lead-plaintiff and discovery developments in the March 2026 securities class action (D. Mass. 4:26-cv-40075). Would show whether litigation forces a financial restatement or settlement.
Key numbers
  • $20.074B FY2025 revenue, up 19.9% year over year (2025-12-31)
  • Stock fell 17.6% in one day on EP guidance cut (2026-02-04)
  • $14.5B Penumbra deal awaits FTC second request review (2026-03-16)
Named risks
  • Continued EP/PFA share loss to Medtronic, J&J and Abbott after Q1 2026 miss. Severity: high
  • Securities class action and derivative litigation over EP sales disclosures filed March 2026. Severity: high
  • Penumbra $14.5B acquisition delayed or blocked after FTC second request March 16, 2026. Severity: medium
  • Stock volatility, down roughly 53% from 12-month high of $109.50 as of July 2026. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Medtronicgaining onEP segment missed consensus by ~$33M in Q1 2026 amid shipped rival PFA devices
Johnson & Johnson/Biosense Webstergaining onCompeting PFA devices contributed to EP guidance cut announced Feb 4, 2026
Abbott LaboratoriescontestingAmplatzer Amulet competes with Watchman; Abbott entering PFA market by 2026
StrykercontestingEntered intravascular lithotripsy via Amplitude Vascular acquisition, reported July 6, 2026
Questions people ask
Is Boston Scientific profitable in 2026?
Yes. Boston Scientific posted FY2025 GAAP net income of $2.898 billion ($1.94 EPS) on $20.074 billion net sales, and Q1 2026 revenue hit $5.20 billion, up 11.6% YoY, beating the $5.19B consensus estimate as of mid-2026.
Is Boston Scientific losing market share in electrophysiology?
Yes, its electrophysiology segment missed consensus by about $33 million in Q1 2026 as Medtronic, J&J/Biosense Webster and Abbott shipped competing pulsed-field-ablation devices, prompting a FY2026 guidance cut to $21.5-21.8B revenue on April 22, 2026.
Will Boston Scientific's Penumbra acquisition close?
Uncertain as of mid-2026. The $14.5 billion Penumbra deal was announced January 15, 2026, but the FTC issued a second request on March 16, 2026, delaying stockholder approval and closing timelines.
Is Boston Scientific stock safe to buy after its 2026 crash?
The stock fell 17.6% in a single day on February 4, 2026 (from $91.62 to $75.50) on an EP guidance cut, and traded near 52-week lows of $42-44 by July 2026, down roughly 53% from its $109.50 12-month high.
Is Boston Scientific facing lawsuits over its electrophysiology business?
Yes. A securities class action (D. Mass., Case No. 4:26-cv-40075) was filed March 5, 2026 alleging management misrepresented EP/Farapulse growth between July 2025 and February 2026, plus a related derivative suit filed March 16, 2026 proceeding through discovery.
How many employees does Boston Scientific have in 2026?
Per company disclosures, headcount reached 59,000 as of December 31, 2025, up 11.3% from 53,000 in 2024, according to a stockanalysis.com report published June 17, 2026.
Timeline
  • 2026-07-20Board approves $5 billion share buyback, up to about 6.4% of shares outstanding
  • 2026-05-18Announces $1.5B, 34% equity stake in MiRus LLC with option to acquire TAVR business
  • 2026-04-22Cuts FY2026 guidance to $21.5-21.8B revenue and $3.34-3.41 adjusted EPS
  • 2026-03-31Signs Scivita Medical agreement with $200M+ earnouts
  • 2026-03-16FTC issues second request on Penumbra deal; derivative suit filed
  • 2026-03-05Securities class action filed alleging EP growth misrepresentation
  • 2026-02-04Reports FY2025 results; stock falls 17.6% in one day on EP guidance cut
  • 2026-01-27Closes Nalu Medical acquisition for about $588 million
  • 2026-01-15Announces agreement to acquire Penumbra for $14.5 billion
Head to head
Boston Scientific vs Olympus Corporation
Revision history
20 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBecton DickinsonEli Lilly
More in Pharma and healthcare groups →
Sources